Replies to post #693892 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Horse,

I agree with you.

Recall that some powerful players forced Al Musella to take down Dr. Liau's webinar video twice. A NWBO investor uploaded the video to Youtube and the video has been shadow blocked. Given that Merck spent $2.3b on advertising last year, I always have suspicion that Merck could be the one which forced Musella to take down the video and Merck could also be the one which has been colluding with the dark forces to suppress the sp. Think about this. With the publication of the Nature article in which it was specifically mentioned that the trial used the vaccine licensed by NWBO, everyone would know that the results presented by Dr. Liau were from the technology licensed by NWBO too if the video were visible to the public, which certainly brings more competitors.

Now two of Merck's competitors already filed for the approval of subcutaneous checking point inhibitors. I tend to believe that Merck's results are not as good as those of the two competitors. Otherwise Merck would have been singing like a canary quite a while ago. I suspect Merck should be under pressure now to show its investors that there is no such issue as patent cliff.

The following is about the PDUFA for BMY and Roche on their subcutaneous checking point inhibitors.

FDA moved the PDUFA date of BMY subcutaneous Opdivo from February 28, 2025 to December 29, 2024. Roche subcutaneous PDUFA is September 15, 2024.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has reassigned the previously announced Prescription Drug User Fee Act (PDUFA) goal date of the Biologics License Application (BLA) for the subcutaneous formulation of Opdivo ® (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. The updated goal date is December 29, 2024.

https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Updated-Action-Date-by-the-U.S.-Food-and-Drug-Administration-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx

https://news.bms.com/news/corporate-financial/2024/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Application-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx